Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06047210

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

Hemophagocytic Lymphohistiocytoses Clinical Trial

Official title:
An Observational, Multicenter Study to Evaluate Levels of Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Adult Patients With Hemophagocytic Lymphohistiocytosis (A-HLH)

Clinical Trial Summary

This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.

Clinical Trial Description

This is a observational study designed to determine the levels of pro-inflammatory markers in adult patients diagnosed with HLH and to assess the relationship between the biomarkers and disease activity in these patients during the HLH course. Inflammatory markers include IFNγ and IFNγ-induced chemokines C-X-C chemokine ligand 9 and C-X-C chemokine ligand 10. In addition to the blood samples for the biomarker analysis, relevant information gathered by the treating physician will be collected in a data collection form. Whenever possible, collection of serum samples for biomarker analysis and relevant information should occur at HLH diagnosis, at regular time intervals during the treatment course (not more than once a week) up to resolution of HLH. Blood samples will also be sent to the study sponsor (NovImmune S.A.) for cytokine testing. Before patient's samples are sent to the sponsor for testing, patient's name and any personal identifying information will be coded to protect participant's privacy. ;

Study Design

Related Conditions & MeSH terms

  • Hemophagocytic Lymphohistiocytoses
  • Lymphohistiocytosis, Hemophagocytic
Clinical Trial Details
NCT number NCT06047210
Study type Observational
Source Swedish Orphan Biovitrum
Contact
Status Completed
Phase
Start date December 14, 2016
Completion date October 30, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05491304 - Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis Phase 4
Completed NCT05531721 - HLH Patients - a Retrospective Study
Not yet recruiting NCT05600959 - Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
Completed NCT03546101 - Early Detection of Epstein-Barr Virus Related Disease.
Recruiting NCT05898477 - Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Recruiting NCT05882175 - Prospective Validation of the OHI Index
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Terminated NCT03985423 - A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Not yet recruiting NCT05677178 - Response Prediction in EBV-HLH Using Metabonomics Analysis
Recruiting NCT03117010 - Prospective Cohort for Adult Hemophagocytosis
Not yet recruiting NCT06160791 - Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) Phase 2
Recruiting NCT05236764 - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion N/A
Recruiting NCT05277272 - INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)
Not yet recruiting NCT05988177 - Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections N/A